Walgreens partners with Epocrates to highlight drug rebates

Share this article:
Walgreens partners with Epocrates to highlight drug rebates
Walgreens partners with Epocrates to highlight drug rebates

Walgreens is hoping physicians will consider its “Prescription Savings Club” list of over 8,000 brand and generic drugs before deciding which script to write for underinsured or cash-strapped patients. Epocrates will provide point of care access to the list via mobile device starting today.

The Prescription Savings Club includes treatments spanning “every drug category” and “most chronic conditions,” like insulin, statins and antivirals, as well as preventative and lifestyle drugs, in categories like weight management, smoking cessation and family planning, according to a statement on the partnership.

Michael Polzin, a spokesperson for Walgreens, said Epocrates was chosen over other mobile drug reference platforms based on its “breadth of use” among physicians. The Prescription Savings Club, which Walgreens describes as a formulary (although it is not affiliated with any health plan), is meant to provide savings to patients without insurance, or filling scripts only partially covered by a health plan. Drug savings are based on the quantitative purchasing power of Walgreens, said Polzin. Walgreens operates 7,580 drugstores in 50 states, and had revenues of $67 billion in fiscal year 2010, according to a statement.

In an April 2009 survey of its users, 68% of physicians (out of 2,075 surveyed) reported having changed a prescribing decision based on formulary information available via Epocrates, according to Erica Sniad Morgenstern, an Epocrates spokesperson.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.